CytomX Therapeutics
Market Cap
US$402.4m
Last Updated
2021/01/24 01:10 UTC
Data Sources
Company Financials +
Executive Summary
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. More Details
Risk Analysis
Earnings are forecast to decline by an average of 17.1% per year for the next 3 years
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet with weak fundamentals.
Share Price & News
How has CytomX Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CTMX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: CTMX's weekly volatility (8%) has been stable over the past year.
Market Performance
7 Day Return
-16.1%
CTMX
1.8%
US Biotechs
2.3%
US Market
1 Year Return
-11.3%
CTMX
45.9%
US Biotechs
23.8%
US Market
Return vs Industry: CTMX underperformed the US Biotechs industry which returned 45.9% over the past year.
Return vs Market: CTMX underperformed the US Market which returned 23.7% over the past year.
Shareholder returns
| CTMX | Industry | Market | |
|---|---|---|---|
| 7 Day | -16.1% | 1.8% | 2.3% |
| 30 Day | -10.4% | 6.7% | 4.8% |
| 90 Day | -1.6% | 24.9% | 14.5% |
| 1 Year | -11.3%-11.3% | 48.3%45.9% | 26.6%23.8% |
| 3 Year | -74.2%-74.2% | 23.3%16.6% | 45.0%35.4% |
| 5 Year | -57.7%-57.7% | 58.9%46.7% | 126.2%101.0% |
Long-Term Price Volatility Vs. Market
How volatile is CytomX Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
How Much Of CytomX Therapeutics, Inc. (NASDAQ:CTMX) Do Institutions Own?1 month ago | Simply Wall St
Here's Why We're Not At All Concerned With CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation2 months ago | Simply Wall St
Analysts Have Made A Financial Statement On CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Third-Quarter ReportValuation
Is CytomX Therapeutics undervalued compared to its fair value and its price relative to the market?
6.4x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CTMX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CTMX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CTMX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CTMX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CTMX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CTMX is overvalued based on its PB Ratio (6.4x) compared to the US Biotechs industry average (4.4x).
Next Steps
Future Growth
How is CytomX Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
-17.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CTMX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CTMX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CTMX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CTMX's revenue (3.9% per year) is forecast to grow slower than the US market (10.6% per year).
High Growth Revenue: CTMX's revenue (3.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CTMX's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has CytomX Therapeutics performed over the past 5 years?
-12.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CTMX is currently unprofitable.
Growing Profit Margin: CTMX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CTMX is unprofitable, and losses have increased over the past 5 years at a rate of 12.5% per year.
Accelerating Growth: Unable to compare CTMX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CTMX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: CTMX has a negative Return on Equity (-111.6%), as it is currently unprofitable.
Next Steps
Financial Health
How is CytomX Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: CTMX's short term assets ($340.3M) exceed its short term liabilities ($102.0M).
Long Term Liabilities: CTMX's short term assets ($340.3M) exceed its long term liabilities ($225.1M).
Debt to Equity History and Analysis
Debt Level: CTMX is debt free.
Reducing Debt: CTMX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CTMX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CTMX has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 29.7% each year.
Next Steps
Dividend
What is CytomX Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CTMX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CTMX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CTMX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CTMX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CTMX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.9yrs
Average management tenure
CEO
Sean McCarthy (53 yo)
9.42yrs
Tenure
US$3,769,930
Compensation
Dr. Sean A. McCarthy, D.Phil., has been the Chief Executive Officer and President of CytomX Therapeutics, Inc. since August 2011 and has been its Chairman since December 31, 2018. Dr. McCarthy joined the C...
CEO Compensation Analysis
Compensation vs Market: Sean's total compensation ($USD3.77M) is above average for companies of similar size in the US market ($USD1.64M).
Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 9.42yrs | US$3.77m | 0.45% $ 1.8m | |
| Co-Founder & Independent Director | 10.33yrs | US$136.50k | 1.15% $ 4.6m | |
| Senior VP | 2.58yrs | US$1.10m | 0.026% $ 102.7k | |
| Executive VP & Chief Development Officer | 1.25yrs | US$3.72m | 0.0067% $ 27.0k | |
| Senior VP & CFO | 0.83yr | no data | 0.0067% $ 27.0k | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Senior Vice President of Process Sciences & Manufacturing Operations | 3.25yrs | no data | no data | |
| Senior Vice President | no data | no data | no data | |
| Senior Vice President of Program & Alliance Management | 3yrs | no data | no data | |
| Senior Vice President of Intellectual Property | 1.92yrs | no data | no data | |
| Senior VP & Chief Medical Officer | 0.92yr | no data | no data | |
| Senior VP & Head of Research | 0.25yr | no data | no data |
1.9yrs
Average Tenure
57yo
Average Age
Experienced Management: CTMX's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 9.42yrs | US$3.77m | 0.45% $ 1.8m | |
| Co-Founder & Independent Director | 10.33yrs | US$136.50k | 1.15% $ 4.6m | |
| Independent Director | 1.67yrs | US$256.71k | 0.00031% $ 1.2k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.58yrs | US$139.62k | 0% $ 0 | |
| Independent Director | 2.08yrs | US$128.12k | 0% $ 0 | |
| Lead Independent Director | 2.08yrs | US$163.87k | 0% $ 0 | |
| Independent Director | 0.75yr | no data | no data | |
| Member of Scientific Advisory Board | 0.083yr | US$1.48m | 0.041% $ 165.8k | |
| Member of Scientific Advisory Board | 1yr | no data | no data | |
| Independent Director | 3.25yrs | US$127.12k | 0% $ 0 | |
| Member of Scientific Advisory Board | 1yr | no data | no data |
2.1yrs
Average Tenure
61.5yo
Average Age
Experienced Board: CTMX's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.2%.
Top Shareholders
Company Information
CytomX Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: CytomX Therapeutics, Inc.
- Ticker: CTMX
- Exchange: NasdaqGS
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$402.392m
- Shares outstanding: 60.51m
- Website: https://www.cytomx.com
Number of Employees
Location
- CytomX Therapeutics, Inc.
- 151 Oyster Point Boulevard
- Suite 400
- South San Francisco
- California
- 94080
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CTMX | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Oct 2015 |
| 6C1 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Oct 2015 |
Biography
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody te...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/24 01:10 |
| End of Day Share Price | 2021/01/22 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.